---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-013555"
form_type: "8-K"
ticker: "DMAC"
cik: "0001401040"
company_name: "DiaMedica Therapeutics Inc."
filed_at: "2022-05-25T23:59:59+00:00"
generated_at: "2026-06-25T07:08:22.426630+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# SVP of Clinical Operations Harry Alcorn resigns from DiaMedica; separation agreement includes salary continuation

## Summary
- Harry Alcorn, Jr., Pharm.D., SVP of Clinical Operations, resigned effective May 23, 2022.
- Separation agreement provides salary continuation for 9 months (up to 12 if unemployed), COBRA, pro-rata bonus, and option acceleration.
- Entered consulting agreement at $200/hour; no fees while receiving salary continuation.
- Alcorn must cooperate with transition, maintain confidentiality, and non-disparagement.

## SEC filing metadata
- accession: 0001437749-22-013555
- form_type: 8-K
- ticker: DMAC
- cik: 0001401040
- company_name: DiaMedica Therapeutics Inc.
- filed_at: 2022-05-25T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401040/000143774922013555/0001437749-22-013555-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401040/000143774922013555/dmtp20220524_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-013555
- JSON: https://secwatch.observer/filing/0001437749-22-013555.json
- Plain text: https://secwatch.observer/filing/0001437749-22-013555.txt

## Key facts
- Executive change
  Harry Alcorn, Jr. resigned as Senior Vice President of Clinical Operations at DiaMedica Therapeutics Inc..
  - Action: resigned
  - Role: Senior Vice President of Clinical Operations
  source text: On May 23, 2022, Harry Alcorn, Jr., Pharm.D., Senior Vice President of Clinical Operations of DiaMedica Therapeutics Inc. (the “Company”), resigned as an officer and employee of the Company and its subsidiaries, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401040/000143774922013555/0001437749-22-013555-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.